🇺🇸 Pamidronatdinatrium in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Agranulocytosis — 2 reports (15.38%)
  2. Osteonecrosis Of Jaw — 2 reports (15.38%)
  3. Urticaria — 2 reports (15.38%)
  4. Atrial Fibrillation — 1 report (7.69%)
  5. Drug Ineffective — 1 report (7.69%)
  6. Fatigue — 1 report (7.69%)
  7. Febrile Neutropenia — 1 report (7.69%)
  8. Fluid Intake Reduced — 1 report (7.69%)
  9. General Physical Health Deterioration — 1 report (7.69%)
  10. Hepatic Cirrhosis — 1 report (7.69%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Pamidronatdinatrium approved in United States?

Pamidronatdinatrium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Pamidronatdinatrium in United States?

University of Aarhus is the originator. The local marketing authorisation holder may differ — check the official source linked above.